Sato A, Kurihara M, Matsukawa M, Yamazaki T, Shimada K, Endo W, Yamazaki T, Nakamachi M
Dept. of Gastroenterology, Toyosu Hospital, Showa University.
Gan To Kagaku Ryoho. 2000 Apr;27(4):617-21.
Two patients with advanced colorectal cancer were consecutively administered two different chemotherapeutic regimens. The first patient showed an initial response to combination treatment with irinotecan plus cisplatin, but then progressed. He subsequently responded to treatment with a novel thymidylate synthase (TS) inhibitor, raltitrexed. The second patient, who progressed after exhibiting a response to raltitrexed, subsequently responded to irinotecan/cisplatin combination therapy. In conclusion, no clinical cross resistance between the regimens of irinotecan/cisplatin combination therapy and raltitrexed was observed in these patients with advanced colorectal cancer.
两名晚期结直肠癌患者连续接受了两种不同的化疗方案。第一名患者对伊立替康加顺铂的联合治疗最初有反应，但随后病情进展。他随后对新型胸苷酸合成酶（TS）抑制剂雷替曲塞治疗有反应。第二名患者在对雷替曲塞有反应后病情进展，随后对伊立替康/顺铂联合治疗有反应。总之，在这些晚期结直肠癌患者中，未观察到伊立替康/顺铂联合治疗方案与雷替曲塞之间存在临床交叉耐药性。
